Crossmark

Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID)

Crossref DOI link: https://doi.org/10.1016/j.eimc.2026.503166

Published Print: 2026-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Caponcello, Maria Giulia

Macías-Sánchez, Maria del Mar

Macías, Juan

Aguilar-Guisado, Manuela

Romero Palacios, Alberto

Retamar-Gentil, Pilar

Márquez-Gómez, Ignacio

Martínez-Marcos, Francisco Javier

López Cárdenas, Salvador

Marrugal-Lorenzo, Jose Antonio

Quijano Ruiz, Blanca

Mata, Rosario

Carmona-Sánchez, Gloria

Oyonarte, Salvador

Rodríguez-Baño, Jesús
Funding

Funding for this research was provided by:

Consejería de Salud y Familias, Junta de Andalucía

Regional Government of Andalucia Department of Health and Families Progress and Health Foundation
License Information

Text and Data Mining valid from 2026-06-01

Text and Data Mining valid from 2026-06-01

Version of Record valid from 2026-03-11
More Information

This article is maintained by: Elsevier

Article Title: Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID)

Journal Title: Enfermedades Infecciosas y Microbiología Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eimc.2026.503166

Content Type: article

Copyright: © 2026 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.

Document is current

Any future updates will be listed below